Fibrosis-Inflammation Lab

⌘K

Fibrosis-Inflammation Lab

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights
Resources
Pathways

Company

About
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

/

/

Zepbound (Tirzepatide) | Accelerate Your Fibrosis Research

Home/Drugs/Zepbound

Zepbound

Tirzepatide

Phase 3

Sponsor: Eli Lilly

Indication: MASH / Obesity

Mechanism of Action

GLP-1/GIP Dual Agonist

Target: GLP-1Target: GIP

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT04039503

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

Phase:PHASE3Org:Eli Lilly and Company

NOT_YET_RECRUITINGNCT07468552

Trial of Tirzepatide for the Treatment of Cannabis Use Disorder

Phase:PHASE2Org:National Institute on Drug Abuse (NIDA)

COMPLETEDNCT05078255

The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

Phase:NAOrg:University Hospital, Gentofte, Copenhagen

RECRUITINGNCT06630585

GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

Phase:PHASE3Org:University of Bern

NOT_YET_RECRUITINGNCT07527910

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Phase:PHASE2Org:Regeneron Pharmaceuticals

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial.

Chen C, Ying Z, Tang Q et al.

Life Metab2025 Oct

Impact of Tirzepatide on FIB-4 in Patients with Type 2 Diabetes: A Comparison between GLP-1RA-naïve and GLP-1RA Switch Initiation in a Retrospective Cohort.

Ito H, I C, Matsushita M et al.

Intern Med2026 Apr 28

Use of semaglutide and tirzepatide among people with multiple sclerosis.

Salter A, Novak A, Lancia S et al.

Mult Scler2026 Apr 29

THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty.

Alzaki AA, Alqahtani MZ, Aman E et al.

Cureus2026 Mar

Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency.

Caputo C

JCEM Case Rep2026 May

View more on PubMed

Validated Models

This drug has been validated in the following preclinical models: